Table 2.

Clinical response to neoadjuvant trastuzumab plus vinorelbine

ResponsePatients (N = 48), n (%)
cCR + cPR42 (88)
    cCR17 (36)
    cPR25 (52)
cSD5 (10)
cPD1 (2)